Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Clin Cancer Res. 2013 Feb 5;19(7):1806–1815. doi: 10.1158/1078-0432.CCR-12-2764

Figure 6. Therapeutic efficacy of MSV/EphA2 in combination with docetaxel on HeyA8-MDR tumors.

Figure 6

Figure 6

Figure 6

Nude mice were inoculated i.p. with HeyA8-MDR cells, and randomly allocated to one of five treatment groups (n = 10): 1) docetaxel (DTX), 2) MSV loaded with non-silencing scramble siRNA-DOPC (MSV/Control, 15 μg), 3) MSV loaded with 15 μg EphA2-siRNA-DOPC (MSV/EphA2, 15 μg), 4) DTX and MSV/Control combination (DTX + MSV/Control), 5) DTX and MSV/EphA2 combination (DTX + MSV/EphA2). Mice were treated biweekly for 6 weeks. At the end of the treatment, all mice were sacrificed, and total tumor weight and the number of tumor nodules were measured. A. Distribution of tumor weight and tumor nodules among the treatment groups. B. Immunohistochemical staining for EphA2 expression, tumor microvessels by CD31, and cell apoptosis by TUNEL assay. C. Quantitation of tumor microvessels and apoptotic cells. Five fields per slide and at least 5 slides per group (all from different animals) were counted. *: p<0.05, **: p<0.01.

HHS Vulnerability Disclosure